I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV626910169US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 16, 2005

Signature Mohea Limenton (Andrea Silverman)

Docket No.: AREX-P03-004

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Madiyalakan et al.

Application No.: 09/376,604

Confirmation No.: 6693

Filed: August 18, 1999

Art Unit: 1642

For:

THERAPEUTIC COMPOSITIONS THAT

ALTER THE IMMUNE RESPONSE

Examiner: G. B. Nickol

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

We bring to the Examiner's attention the following co-owned, co-pending applications in which Office Actions may have issued: U.S. Application No. 09/152,698, U.S. Application No. 09/871,339, U.S. Application No. 09/994,466, U.S. Application No. 10/754,089, U.S. Application No. 10/824,554, and U.S. Application No. 10/831,886.

Applicants have not provided copies of these applications herewith, but will do so upon request by the Examiner.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this

9596944.1

05/18/2005 SSESHE1 00000014 181945 09376604

02 FC:1806

180.00 DA

Application No.: 09/376604 Docket No.: AREX-P03-004

Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. AREX-P03-004. A duplicate copy of this paper is enclosed.

Dated: May 16, 2005

Respectfully submitted,

Gloria Fuentes

Registration No.: 47,580 FISH & NEAVE IP GROUP ROPES & GRAY LLP 1251 Avenue of the Americas New York, New York 10020 (212) 596-9337 (212) 497-3650 (Fax)